Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
复制标题
DOI：
10.21873/anticanres.15635
复制
发表时间：
2022-02
影响因子：
2
通讯作者：
Takuro Okada;C. Fushimi;T. Matsuki;I. Okamoto;HIROKI SATO-;T. Kondo;Kunihiko Tokashiki;T. Kishida;T. Ito;Gai Yamashita;Yusuke Aihara;Kenji Hanyu;Yukiomi Kushihashi;T. Masubuchi;Y. Tada;K. Miura;Y. Harada;Kaho Momiyama;T. Yamashita;G. Omura;Hideaki Takahashi;N. Oridate;K. Tsukahara
中科院分区：
文献类型：
--
作者：
Takuro Okada;C. Fushimi;T. Matsuki;I. Okamoto;HIROKI SATO-;T. Kondo;Kunihiko Tokashiki;T. Kishida;T. Ito;Gai Yamashita;Yusuke Aihara;Kenji Hanyu;Yukiomi Kushihashi;T. Masubuchi;Y. Tada;K. Miura;Y. Harada;Kaho Momiyama;T. Yamashita;G. Omura;Hideaki Takahashi;N. Oridate;K. Tsukahara
背景/目的：对于复发性/转移性头颈部鳞状细胞癌（R/M SCCHN），没有3 mg/kg和240 mg/个体nivolumab剂量的真实世界比较数据。我们使用真实世界数据研究了不同剂量的纳武利尤单抗治疗头颈部复发性/转移性鳞状细胞癌（R/M SCCHN）的疗效和安全性。患者和方法：将接受纳武利尤单抗的R/M SCCHN患者分为3 mg/kg和240 mg/体组，并回顾性检查疗效和安全性。结果：共纳入199例患者（3 mg/kg和240 mg/体，分别为88例和111例）。3 mg/kg组与240 mg/kg组的总缓解率（15%与25，p=0.15）、疾病控制率（46%与57%，p=0.15）、总生存期（9.5个月与10.9个月）和无进展生存期（3.7个月与3.8个月，p=0.95）相似。两组中免疫相关不良事件的发生率也相似。结论：在R/M SCCHN患者中，nivolumab在3 mg/kg和240 mg/体的剂量下显示出相似的疗效和安全性。
Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.